Showing results (111-120 of 121) with videos related to
Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|August 24, 2007
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifenN I Ntukidem, A T Nguyen, V Stearns, et al.Breast Cancer Research and Treatment|December 28, 2011
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivoB Ramaswamy, W Fiskus, B Cohen, et al.Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999P L Fitzgibbons, D L Page, D Weaver, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancerS M Baidas, E P Winer, G F Fleming, et al.Breast Cancer Research and Treatment|July 10, 2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerZ A Nahleh, W E Barlow, D F Hayes, et al.British Journal of Cancer|October 3, 2013
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effectsN L Henry, H-P Chan, J Dantzer, et al.The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.Molecular Endocrinology (Baltimore, Md.)|December 17, 2011
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in boneR J Hartmaier, A S Richter, R M Gillihan, et al.Clinical Pharmacology and Therapeutics|March 7, 2007
The pharmacogenetics research network: from SNP discovery to clinical drug responseK M Giacomini, C M Brett, R B Altman, et al.Pageof 13